JP2022105138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022105138A5 JP2022105138A5 JP2022075664A JP2022075664A JP2022105138A5 JP 2022105138 A5 JP2022105138 A5 JP 2022105138A5 JP 2022075664 A JP2022075664 A JP 2022075664A JP 2022075664 A JP2022075664 A JP 2022075664A JP 2022105138 A5 JP2022105138 A5 JP 2022105138A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 39
- 108091008324 binding proteins Proteins 0.000 claims 15
- 102000023732 binding proteins Human genes 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 102000052088 human IL3RA Human genes 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305923 | 2016-07-18 | ||
| EP16305923.1 | 2016-07-18 | ||
| JP2019502257A JP7071329B2 (ja) | 2016-07-18 | 2017-07-17 | Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 |
| PCT/EP2017/068020 WO2018015340A1 (en) | 2016-07-18 | 2017-07-17 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502257A Division JP7071329B2 (ja) | 2016-07-18 | 2017-07-17 | Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022105138A JP2022105138A (ja) | 2022-07-12 |
| JP2022105138A5 true JP2022105138A5 (enExample) | 2022-10-12 |
Family
ID=56507555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502257A Active JP7071329B2 (ja) | 2016-07-18 | 2017-07-17 | Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 |
| JP2022075664A Pending JP2022105138A (ja) | 2016-07-18 | 2022-05-02 | Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502257A Active JP7071329B2 (ja) | 2016-07-18 | 2017-07-17 | Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241657A1 (enExample) |
| EP (1) | EP3484924A1 (enExample) |
| JP (2) | JP7071329B2 (enExample) |
| KR (1) | KR20190028771A (enExample) |
| CN (1) | CN109715665A (enExample) |
| AR (1) | AR109264A1 (enExample) |
| AU (1) | AU2017299125A1 (enExample) |
| BR (1) | BR112019000770A2 (enExample) |
| CA (1) | CA3030943A1 (enExample) |
| CL (1) | CL2019000119A1 (enExample) |
| CO (1) | CO2019001367A2 (enExample) |
| CR (1) | CR20190072A (enExample) |
| DO (1) | DOP2019000011A (enExample) |
| EA (1) | EA201990321A1 (enExample) |
| EC (1) | ECSP19011185A (enExample) |
| IL (1) | IL264248A (enExample) |
| MA (1) | MA45680A (enExample) |
| MX (1) | MX2019000844A (enExample) |
| PE (1) | PE20190514A1 (enExample) |
| PH (1) | PH12019500122A1 (enExample) |
| SG (1) | SG11201900400QA (enExample) |
| TN (1) | TN2019000015A1 (enExample) |
| TW (1) | TWI790206B (enExample) |
| WO (1) | WO2018015340A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3247725B1 (en) | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| AU2019371243A1 (en) * | 2018-10-30 | 2021-05-27 | Bruker Spatial Biology, Inc. | Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies |
| MA55305A (fr) | 2019-03-11 | 2022-01-19 | Janssen Biotech Inc | Anticorps bispécifiques anti-v béta 17/anti-cd123 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| CN111171155B (zh) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| WO2022035722A1 (en) | 2020-08-10 | 2022-02-17 | Janssen Biotech, Inc. | Materials and methods for producing bioengineered virus specific lymphocytes |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| EP4271709A1 (en) * | 2020-12-31 | 2023-11-08 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| MX2023009615A (es) * | 2021-02-17 | 2023-08-24 | Igm Biosciences Inc | Moleculas de union anti-cd123 y usos de estas. |
| CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
| CA3224408A1 (en) * | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| JP2546544B2 (ja) | 1989-10-27 | 1996-10-23 | アーチ ディベラップメント コーポレイション | 免疫強化を促進するための方法と組成物 |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| CA2098824A1 (en) | 1990-12-20 | 1992-06-21 | William D. Huse | Optimization of binding proteins |
| AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| JP2004509835A (ja) | 2000-03-06 | 2004-04-02 | ユニヴァーシティ オブ ケンタッキー リサーチ ファンデーション | 血液癌前駆細胞を障害する方法およびその関連化合物 |
| SI2195023T1 (en) | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| PT2748201T (pt) * | 2011-08-23 | 2018-02-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas que ativam as células t |
| EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| CA2941958A1 (en) * | 2013-12-10 | 2015-06-18 | F. Hoffmann-La Roche Ag | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
| RS60305B1 (sr) * | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
| CN116333153A (zh) * | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| EP3247725B1 (en) * | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh not_active IP Right Cessation
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 CA CA3030943A patent/CA3030943A1/en active Pending
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/en not_active Withdrawn
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/en not_active Ceased
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Withdrawn
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja active Active
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022105138A5 (enExample) | ||
| JP2025032102A5 (enExample) | ||
| JP2024075713A5 (enExample) | ||
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2022177090A5 (enExample) | ||
| JP2022061992A5 (enExample) | ||
| JP2020537644A5 (enExample) | ||
| JP2023081303A5 (enExample) | ||
| RU2012101485A (ru) | Биспецифические четырехвалентные антигенсвязывающие белки | |
| JP2024167313A5 (enExample) | ||
| RU2010119521A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| RU2009122514A (ru) | Молекулы, связывающие белок lingo, и их фармацевтическое применение | |
| JP2008508859A5 (enExample) | ||
| RU2006115835A (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| TW201241180A (en) | Dual variable domain immunoglobulins and uses thereof | |
| RU2011153016A (ru) | Три- или тетраспецифические антитела | |
| JP2009165471A (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| TW201124534A (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2010511388A5 (enExample) | ||
| RU2005115477A (ru) | Нейтрализующие антитела против gdf-8 и их применение | |
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| JPWO2019156137A5 (enExample) | ||
| JP2018504112A5 (enExample) | ||
| JPWO2020059847A5 (enExample) |